

# **APPLICATION OF NANOTECHNOLOGY IN NATURAL COMPOUNDS FOR ANTIOXIDANT AND ANTICANCER PREPARATIONS**

**By**

**SAMAR ABD ELRAHEEM AHMAD ALI SHAHIN**

**B.Sc. Agric. Sci. (Biotechnology), Fac. Agric., Cairo Univ., 2007**

## **THESIS**

**Submitted in Partial Fulfillment of the  
Requirements for the Degree of**

## **MASTER OF SCIENCE**

**In**

**Agricultural Sciences  
(Agricultural Biochemistry)**

**Department of Agricultural Biochemistry  
Faculty of Agriculture  
Cairo University  
EGYPT**

**2019**

**Format Reviewer**

**Vice Dean of Graduate Studies**

**APPROVAL SHEET**

**APPLICATION OF NANOTECHNOLOGY IN  
NATURAL COMPOUNDS FOR ANTIOXIDANT  
AND ANTICANCER PREPARATIONS.**

**M.Sc.Thesis  
In  
Agric. Sci. (Agricultural Biochemistry)**

**By**

**SAMAR ABD ELRAHEEM AHMAD ALI SHAHIN**  
B.Sc. Agric. Sci. (Biotechnology), Fac. Agric., Cairo Univ., 2007

**APPROVAL COMMITTEE**

**Dr.ASHRAF ABDO TABL.....**

Professor of Medicinal Technology, National Research Centre (NRC).

**Dr.EMAM ABD EL-MOBDEA ABD EL-RAHEEM.....**

Professor of Biochemistry, Fac. Agric., Cairo University

**Dr. FATEN MOHAMMAD ABOUL-ELA.....**

Professor of Biochemistry, Fac. Agric., Cairo University

**Dr. AHMAD MAHMOUD ABOUL-ENEIN.....**

Professor of Biochemistry, Facu. Agric., Cairo University

**Date:** 28 / 8 /2019

**SUPERVISION SHEET**

**APPLICATION OF NANOTECHNOLOGY IN  
NATURAL COMPOUNDS FOR ANTIOXIDANT  
AND ANTICANCER PREPARATIONS**

**M.Sc. Thesis**

**In**

**Agric. Sci. (Agricultural Biochemistry)**

**By**

**SAMAR ABD ELRAHEEM AHMAD ALI SHAHIN**

**B.Sc. Agric. Sci. (Biotechnology), Fac. Agric., Cairo Univ., 2007**

**SUPERVISION COMMITTEE**

**Dr. AHMED MAHMOUD ABOUL-ENEIN**

**Professor of Biochemistry, Fac. Agric, Cairo University**

**Dr. FATEN MOHAMMED ABOUL-ELA**

**Professor of Biochemistry, Fac. Agric., Cairo University**

**Dr. KHALED ABOU-AITAH**

**Researcher of Medicinal and Aromatic Plants, National Research Centre (NRC)**

**Name of candidate:** Samar Abd Elraheem Ahmad Ali Shahin      **Degree:** M.Sc.  
**Title of Thesis:** Application of Nanotechnology in Natural Compounds  
for Antioxidant and Anticancer Preparations  
**Supervisors:** Dr. Ahmed Mahmoud Aboul-Enein  
Dr. Faten Mohamed Abou-Elella  
Dr. Khaled AbouAitah  
**Department:** Agricultural Biochemistry  
**Date:** 28 /8 /2019

### ABSTRACT

As multi-targeted compound, Thymoquinone (TQ) has been showed numerous therapeutic potentials in different diseases including cancers. Piperine has a wide range of pharmacological properties. It is used as an antioxidant, anti-cancer, etc, still not yet reach clinical use. This because some inherit limitations, as low bioavailability and solubility, targeting delivery, and selectivity. Here, in present studies have successfully tailored novel nanoformulations for TQ delivery relay on mesoporous silica nanoparticles (MSNs) as nanocarrier, and for Pip delivery relay on hydroxyapatite (HAP) as nanocarrier and made modification by adding phosphonate group (HAP-H). TQ loaded into mesoporous of MSNs as core (MSNTQ), subsequently step, coating of the core with mixture of two different polymers-based designs to obtain shell layer (MSNTQ-WA, Whey protein-Arabic gum, and MSNTQ-CS, Chitosan-Stearic acid). The anticancer efficiency and selectivity in brain cancer cells (SW1088 and A172) compared to brain normal ones (HCN2) were investigated. The anticancer efficiency and selectivity of (HAP-Pip, HAP-H-Pip and Pip) in breast cancer cells (MCF7), colon cancer cells (CaCo2) and normal lungs (WI38) cell were used as normal cells. Furthermore . The results demonstrated that anticancer activity in term of cell viability was varied and found to be cell line- With respect of biocompatibility of nanocarrier, and less toxic on normal than cancer cells Going further, the selective index calculations based on  $IC_{50}$  values verified that MSNTQ-WA, HAP-H-Pip exhibited better selectivity compared to all. Collectively, as the molecular mechanisms of action are concerned, the important findings is that nanoformulations especially MSNTQ-WA allowed remarkable effect to improve caspase-3 activation, Cytochrom c triggers, cell cycle arrest at G2/M phase and HAP-H-Pip has apoptosis induction compared to Pi in brain cancer cells.

**Keywords:** Cancer selectivity, Drug delivery systems, Thymoquinone nanoformulations, Mesoporous silica nanoparticles, Brain cancers. Piperine nanoformulations, Hydroxyapatite nanoparticles, Breast and colon cancer.

## DEDICATION

*I dedicate this work to whom my heartfelt ,to my late **father** and my beloved queen **mother** whose taught me how to fight with honor till I reach my goal;my (**brother** and **sisters**) whose encouraged me when I fall down ; my small family (**Husband** and **Son**) for all the support they lovely offered along the period of my post-graduation; **Mohammad Ebrahim,Amr Abou-Elhamad and Elshaimaa Ahmad** whose supported me a lotto continueandfinally **my colleagues** whom help, support me a lot and encouraged me when I faint ; and your support made me able to gain such success and honor.*

*Thanks from the earth to the edge of the universe.*

## ACKNOWLEDGMENTS

*First, I would like to express my great thanks to Allah, for giving me the patience and the power to overcome all problems, which faced me throughout this work.*

*I would like to express my greatest appreciation, deepest thanks to my supervisor **Dr. Ahmed Aboul-Enein**, Prof. of Biochemistry, Faculty of Agriculture, Cairo University for his encouragement and his beneficial criticism, indispensable advice, helpful suggestions, his valuable supervision and valuable time devoted during the preparation of this thesis.*

*I am profoundly grateful to **Dr. Faten Aboul-Ela**, Prof. of Biochemistry, Faculty of Agriculture, Cairo University for her kind supervision, continuous encouragement, comments and the time she freely gave me during this work.*

*I would like to express my great indebtedness, deepest thanks and sincere gratitude to my supervisor **Dr. Khaled Abou-Eitta**, Researcher, Medicinal and Aromatic Plants Research Department, National Research Center, for suggesting the subject her valuable supervision constant beneficial criticism indispensable advice, generous help, and supplying all the facilities throughout the whole time of this work.*

*I wish to express my indebtedness and profound gratitude to **Dr. Abdalla M. A. Abdullah**, Professor of Agricultural biometry agronomy department faculty of Agriculture, Cairo University. For statistical analysis to the obtained data.*

*I wish to express my indebtedness and profound gratitude to **Dr. Esam R. Ahmed**, Confirmatory Diagnostic Unit, (VACSERA), Giza, Egypt.*

## LIST OF ABBREVIATIONS

API=Active Pharmaceutical Ingredient.  
BBB=the blood-brain barrier.  
BET=Brunauer-Emmett-Teller.  
CAT=catalase.  
CTAB= Cetyltrimethylammonium bromide.  
CS= Chitosan.  
DDSs= Drug delivery systems.  
Dime DFT= Density functional theory.  
Dimethylsulfoxide = DMSO.  
DOX=Anticancer drug doxorubicin.  
DPPH=(2,2-diphenyl-1-picrylhydrazyl).  
DSC=Differential Scanning Calorimetry.  
2D-NMR=Two-dimensional nuclear magnetic resonance.  
3D=Three dimensional.  
EDC=1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride.  
EGCG=Epigallocatechin- 3-gallate.  
ERK =extracellular-signal-regulated kinase.  
FA=Folic acid.  
FACS=Fluorescence-activated cell sorting.  
FTIR=Fourier transform infrared spectroscopy.  
Fourier Transform Infrared spectroscopy.  
GPx=glutathione peroxidase.  
GRed= glutathione reductase  
HAP=Hydroxyapatite Nanoparticles.  
HR-TEM=High resolution transmission electron microscopy.  
HPLC= High Performance Liquid Chromatography.  
HP=Hydroxyapatite .  
HSNPs=Hollow silica nanoparticles.  
KCC-1=Fibrous silica nanospheres introduced by KAUST Catalysis Center.  
MCM-41=Mobil Composition of Matter No. 41 mesoporous silica material.  
MMP9=Matrix metalloproteinase 9.  
MSNs=Mesoporous silica nanoparticles.

MSNTQ-CS= Mesoporous silica nanoparticles thymoquinone-chitosan-stearic acid .  
MSNTQ-WA= Mesoporous silica nanoparticles thymoquinone-Whey protein-Arabic gum.  
MTX=Methotrexate.  
NF- $\kappa$ B=Nuclear factor kappa-light-chain-enhancer of activated B cells.  
PBS=Phosphate buffer saline.  
PCS=photon correlation spectroscopy.  
PI3K/AKT=Phosphatidylinositol-3-kinases/AKT pathway  
PIP= Piperine.  
PKC= Protein kinase C.  
PLGA = Poly(D, L-lactide-co-glycolide  
Prx=peroxiredoxin  
PPAR- $\gamma$ =Peroxisome proliferator-activated receptor gamma.  
PTA-CS-MNP=phytic acid-chitosan-iron oxide nanocomposite.  
PXRD=powder X-ray diffraction.  
SEM=Field emission scanning electron microscopy.  
SLN=Solid lipid nanoparticle.  
SOD=Superoxide dismutase  
STA-FTIR=Simultaneous Thermal Analysis coupled with  
TBAR= Tthio-barbituric acid-reactive.  
TEA=Triethanolamine  
TEM=transmission electron microscopy.  
TEOS=Tetraethyl orthosilicate.  
TGA=Thermogravimetric analysis.  
TLC=Thin Layer Chromatography.  
TQ=Thymoquinone.  
WHO=World Health Organization.  
XIAP= X-linked inhibitor apoptosis protein.  
XRD=X-Ray diffraction.



# CONTENTS

	Pages
<b>INTRODUCTION.....</b>	<b>1</b>
<b>REVIEW OF LITERATURE.....</b>	<b>6</b>
<b>1. Cancer Disease.....</b>	<b>6</b>
<b>2. Role of Plants As Medicinal and Anti-Cancer Agents.....</b>	<b>9</b>
a. Medicinal plants.....	9
b. Plant compounds with anticancer properties.....	10
(1) Polyphenols.....	11
(2) Flavonoids.....	12
<b>3. Plants used in the present study.....</b>	<b>13</b>
a. <i>Nigella Sativa</i> (The Black Seed) herb.....	13
(1)Thymoquinone (TQ).....	13
b .Black pepper.....	18
(1) Piperine.....	19
<b>4. Cell Cycle and Apoptosis.....</b>	<b>22</b>
<b>5. Apoptosis.....</b>	<b>23</b>
<b>6. Nanotechnology.....</b>	<b>24</b>
<b>7. Nanoparticles.....</b>	<b>26</b>
<b>8. Nanosystems for drug delivery.....</b>	<b>28</b>
a.Mesoporous silica Nanoparticles (NPs).....	31
b.Hydroxyapatite Nanoparticles (HAP) .....	35
<b>9. Characterization techniques of Nanoparticles.....</b>	<b>37</b>
a. Electron microscopy.....	37
b. Thermogravimetric analysis (TGA).....	39
c. X-Ray Diffraction (XRD).....	39
d. Differential Scanning Calorimetry(DSC).....	40
e. Simultaneous thermal analysis coupled to Fourier transforms Infrared spectroscopy (STA-FTIR).....	40
f. Fourier Transform Infrared spectroscopy (FT-IR) .....	41
g. Nitrogen Sorption.....	42
h. Zeta Potential measurements.....	43
<b>10. Antioxidant.....</b>	<b>44</b>
a. Antioxidant System.....	44
b. Antioxidant activity.....	45
<b>Materials and Methods.....</b>	<b>47</b>

<b>1. Materials</b>	<b>47</b>
<b>2. Thymoquinon preparation</b>	<b>48</b>
a. Synthesis of mesoporous silica nanoparticles (MSNs)	48
b. Thymoquinone loading in MSNs and preparation of core- shell nanoformulations	49
c. The core-shell nanoformulation systems	49
d. Characterization techniques	51
<b>3. Piperine Preparation</b>	<b>52</b>
a- Synthesis of Hydroxyapatite nanoparticles	52
b-Preparation of piperine loading	53
<b>4. Cytotoxcity activity</b>	<b>53</b>
a. Cell cultures	53
b. <i>In vitro</i> cytotoxcity assessment	53
<b>5. Apoptosis detection</b>	<b>55</b>
a. Cell cycle analysis by flow cytometry	55
b. Caspase-3 activity assay	56
c. Cytochrom c quantitative analysis by RT-PCR	57
<b>6. Antioxidant activity DPPH radical scavenging assay</b>	<b>58</b>
a. Preparation of tested compounds	58
b. DPPH assay	58
<b>RESULTS AND DISCUSSION</b>	<b>60</b>
<b>1. Synthesis and fabrication of Thymoquinone delivery     systems</b>	<b>60</b>
<b>a. Characterization of MSNs and nanoformulations</b>	<b>60</b>
(1) HR-TEM Images of synthesized mesoporous silica nanomaterial's	62
(2) HR-TEM images of mesoporous silica nanomaterials before and after drug loading and coating with polymer shells	62
(3) FE-SEM images of mesoporous silica nanomaterial's before and after drug loading and coating with polymer shells	64
(4) Nitrogen adsorption-desorption isotherms and pore size distributions measurements of all materials	66
(5) The TGA and DSC measurements	67
(6) FTIR spectra of different materials of before and after loading coating with polymers, pure TQ, and polymers	68
<b>b)-<i>In vitro</i> biocompatibility of MSNs nanocarrier</b>	<b>69</b>

(1) <i>In vitro</i> cytotoxicity of mesoporous silica nanoparticles (MSNs) as nanocarrier for the biocompatibility evaluations on brain cancer cells SW1088 after 48 h and 72 h of incubation with cells.....	70
(2) <i>In vitro</i> cytotoxicity of mesoporous silica nanoparticles (MSNs) as nanocarrier for the biocompatibility evaluations on brain cancer cells (A172) after 48h and 72h of incubation with cells.....	72
(3) <i>In vitro</i> cytotoxicity of mesoporous silica (MSNs) nanoparticles as nanocarrier for the biocompatibility evaluations on normal brain cells (HCN2) after 48 h and 72h of incubation with cells.....	73
<b>c. <i>In vitro</i> anticancer selectivity of fabricated designs of nanoformulations for brain cancer cells.....</b>	<b>74</b>
(1) <i>In vitro</i> cytotoxicity of core nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA),and TQ in free form on brain cancer cells SW1088 after 48 h and 72 h of incubation with cells.....	77
(2) <i>In vitro</i> cytotoxicity of core nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA),and TQ in free form on brain cancer cells A172 after 48 h and 72 h of incubation with cells.....	79
(3) <i>In vitro</i> cytotoxicity of core nanoformulation (MSNTQ) and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA),and TQ in Free form on brain normal cells (HCN2) after 48 h and 72 h of incubation with cells.....	81
<b>d. Nanoformulations improve caspase-3 activation in brain cancer cells.....</b>	<b>80</b>
Molecular mechanism of (MSNTQ targets core nanoformulation), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA), and TQ in free form on brain cancer cells (SW1088 and A172),and normal brain cells (HCN2) after 48 h and 72 h of incubation with cells.....	83
<b>e. Nanoformulations improve intracellular release of Cytochrom c in brain cancer cells.....</b>	<b>83</b>

(1) Molecular Cytochrom C mechanism of targets core nanoformulation (MSNTQ) and core-shell nano formulations (MSNTQ-CS and MSNTQ-WA), and TQ in free form on brain cancer cells (SW1088 after 48 h and 72 h of incubation with cells.....	84
(2) Molecular Cytochrom C mechanism of targets core nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA),and TQ in free form on brain cancer cells (A172) after 48 h and 72 h of incubation with cells.....	84
<b>f. Nanoformulations improve cell cycle arrest at G2/M phase in brain cancer cells.....</b>	<b>85</b>
<b>g. Nanoformulations improve apoptosis induction in brain cancer cells.....</b>	<b>89</b>
<b>h. Antioxidant activity.....</b>	<b>91</b>
Free radical scavenging activity of core nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA)and TQ in free form measured by DPPH assay.....	92
<b>2. Piperine nanoformulation.....</b>	<b>93</b>
<b>a. Characterization of Hydroxyapatite (HP) nanoparticles.....</b>	<b>93</b>
<b>b. <i>In vitro</i> biocompatibility of HAP and HAP-H nanocarrier.....</b>	<b>93</b>
(1) <i>In vitro</i> cytotoxicity of Hydroxyapatite (HP) and Hydroxyapatite-H (HP) as nanocarrier for the biocompatibility evaluations on breast cancer cells MCF7 after 48h and 72 h of incubation with cells.....	95
(2) <i>In vitro</i> cytotoxicity of Hydroxyapatite (HP) and for the biocompatibility evaluations on Colon cancer cells CaCo2 after 48h and 72h of incubation with cells.....	97
(3) <i>In vitro</i> cytotoxicity of Hydroxyapatite (HP),Hydroxyapatite-H (HP-H) as nanocarrier for the biocompatibility evaluations on normal Lung cells (WI38)after 48 h and 72 h of Incubation with cells.....	98
(4) IC <sub>50</sub> of HP, HP-H, HP-Pip, HP-H-Pip and Pip against MCF7, CaCo2 and WI38 after48 h and 72h.....	99

<b>c. <i>In vitro</i> anticancer selectivity of nanoformulation (HP-Pip, HP-H-Pip).....</b>	<b>100</b>
(1) <i>In vitro</i> cytotoxicity of core nanoformulation(HP-Pip, HP-H-Pip) and Pip in free form on breast cancer cells MCF7 after 48 h and 72 h of incubation with cells.....	101
(2) <i>In vitro</i> cytotoxicity of nanoformulation (HP-Pip, HP-H-Pip), and Pip in free form on Colon cancer cells CaCo2 after 48 h and 72 h of incubation with cells.....	102
(3) <i>In vitro</i> cytotoxicity of core nanoformulation(HP-Pip and HP-H-Pip) and Pip in free form on lung normal cells (WI38) after 48 h and 72h of incubation with cells.....	104
<b>d. Nanoformulations and caspase-3 activation in breast, colon cancer cells.....</b>	<b>103</b>
Molecular Caspase-3 mechanism of targets core nanoformulation HP-Pip and HP-H-Pip, and Pip in free form on breast cancer Cells (MCF7) and breast cancer cells (CaCo2), and normal Lung cells (WI38) after 48 h and 72 h of incubation with cells.....	107
<b>Conclusion.....</b>	<b>107</b>
<b>Summary.....</b>	<b>110</b>
<b>References.....</b>	<b>119</b>
<b>Arabic Summary.....</b>	

## LIST OF TABLES

NO	Title	Pages
1.	Physicochemical properties of mesoporous silica nanoparticles before and after loading of Thymoquinone.....	65
2.	Cytotoxicity of MSNs against cancer cells SW1088 for 48h and 72h.....	71
3.	Cytotoxicity of MSNs against cancer cells A172 for 48h and 72h.....	72
4.	Cytotoxicity of MSNs against normal HCN2 cell for 48h and 72h.....	73
5.	IC <sub>50</sub> of MSN, MSNTQ, MSNTQN-CS, MSNTQ-WA and TQ against SW1088, A172 and HCN2 for 48h and 72h.....	74
6.	<i>In vitro</i> cytotoxicity of core nanoformulation (MSNTQ) and core-shell nanoformulation (MSNTQ-CS and MSNTQ-WA), and TQ in free form on brain cancer cells SW1088 after 48 h (A) and 72 h (B) of incubation with cells.....	78
7.	<i>In vitro</i> cytotoxicity of core nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA),and TQ in free form on brain cancer cells A172 after 48 h (A) and 72 h (B) of incubation with cells.....	80
8.	<i>In vitro</i> cytotoxicity of core-nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA),and TQ in free form on brain normal Cells (HCN2) after 48 h(A) and 72 h (B) of incubation with cells.....	82

9.	Molecular Caspase-3 mechanism of targets core nanoformulation (MSNTQ), and core-shell nanoformulations core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA), and TQ in free form on brain cancer cells (SW1088 and A172), and normal brain cells (HCN2) after 48 h and 72 h of incubation with cells.....	84
10.	Molecular Cytochrom c mechanism of targets core nanoformulation (MSNTQ) and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA), and TQ in free form on brain cancer cells SW1088 after 48 h and 72 h of incubation with cells.....	87
11.	Molecular cytochrom c mechanism of targets core nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ- WA), and TQ in free form on brain cancer cells A172 after 48 h and 72 h of incubation with cells.....	89
12.	Free radical scavenging activity of core nanoformulation (MSNTQ), and core-shell nanoformulations (MSNTQ-CS and MSNTQ-WA), and TQ in free form measured by DPPH assay.....	92
13.	<i>In vitro</i> Cytotoxicity of Hydroxyapatite (HP) and (HAP-H) Hydroxyapatite-H against MCF7 cancer cells for 48h and 72h.....	96
14.	<i>In vitro</i> cytotoxicity of Hydroxyapatite nanoparticles (HP,HP-H) against CaCo2 cancer for 48h and 72h.....	98
15.	Cytotoxicity of HP and HP-H against normal WI38 cell after 48h and 72h.....	99
16.	IC <sub>50</sub> of HP, HP-H, HP-Pip, HP-H-Pip and Pip against MCF7, CaCo2 and WI38 after 48h and 72h.....	99
17.	<i>In vitro</i> cytotoxicity of nanoformulation HAP-Pip and HAP-H-Pip and Pip in free form on breast cancer cells MCF7 after 48h (A) and 72h (B) of incubation with cells.....	102